Trevi Therapeutics (TRVI) Non-Current Assets (2018 - 2026)

Trevi Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 151.99% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (up 21.74% YoY), and the FY2025 full-year result was $1.8 million, up 21.13% from the prior year.
• Non-Current Assets for Q1 2026 stood at $3.5 million, up from $1.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $3.5 million in Q1 2026, with the low at $399000.0 in Q4 2022.
• Average Non-Current Assets over 5 years is $1.6 million, with a median of $1.6 million recorded in 2024.
• Year-over-year, Non-Current Assets soared 365.16% in 2023 and plunged 33.91% in 2025.
• Tracing TRVI's Non-Current Assets over 5 years: stood at $399000.0 in 2022, then soared by 365.16% to $1.9 million in 2023, then retreated by 20.69% to $1.5 million in 2024, then increased by 21.13% to $1.8 million in 2025, then jumped by 95.46% to $3.5 million in 2026.
• The last three Non-Current Assets figures came in at $3.5 million (Q1 2026), $1.8 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.

Peer Comparison